Efficacy of oral nutritional supplementation for interstitial lung disease with a tendency to weight loss

Abe Mitsuhiro0 个研究点目标入组 25 人开始时间: 2023年7月13日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with a diagnosis of interstitial lung disease.
•2) Patients aged 20 years or older at the time of obtaining consent
•3) Patients who have lost at least 2 kg in the last 12 months or have a BMI <20 kg/m2 in the last 12 months
•4) Patients who have been fully informed of the study and who, on the basis of a thorough understanding of the study, have provided written consent to participate in the study.

•1) Patients with coexisting malignant diseases
•2) Patients with conditions that may further worsen their nutritional status, such as unstable diabetes mellitus
•3) Patients already taking oral nutritional supplements at least once a week within the last 3 months
•4) Patients receiving new medication within the past month for diarrhoea as a side effect of antifibrotic drugs
•5) Patients allergic to milk, soya or gelatine, which are ingredients of Isocal 100
•6) Patients who cannot give their consent
•7) Other patients who are judged by the study investigator or sub-investigator to be unsuitable for the safe conduct of the study.

发起方

Abe Mitsuhiro